ATMI announces technology investment with Medinstill

Published: 24-Sep-2013
Manufacturing

Partnership to deliver sterile connector and fill technology


ATMI, a leader in single-use bioprocess solutions, has invested in sterile connector and sterile fill technology developed by Medical Instill Technologies (Medinstill), a developer of solutions for the transfer and packaging of high purity fluids at high safety levels.

The investment focuses on Medinstill's INTACT family of products, which will be deployed in sterile filling, sterile multiple-dose dispensing, sterile transfer, and packaging sterilisation solutions for the pharmaceutical, biotech, and healthcare industries.

'ATMI has a strong history of internal innovation as well as collaboration with other innovators,' said Doug Neugold, Chief Executive of ATMI.

'Collaboration with Medinstill is another great example of this strategy. Through this investment, we will develop a suite of products that address critical issues from our customers’ perspective as they continue to adopt single-use technology and other new inventions.'

'We are happy to partner with a company of ATMI’s stature,' added Daniel Py, Chairman of Medinstill. 'With its global reach and history of technical innovation in biopharmaceutical manufacturing, I believe ATMI can be instrumental in allowing us to bring products with the highest safety levels to those in need.'

INTACT Filler technology allows for sterile fill of multiple products into a broad range of containers and dosing devices in conditions significantly less stringent and less expensive than cleanrooms. ATMI and Medinstill have formed a joint venture to market and manufacture this technology, which is scalable from small lots in benchtop systems to industrial scales in the global biopharmaceutical and vaccine markets.

INTACT Connector technology will allow for sterile re-use of disposable connectors and ATMI has exclusively licensed this technology for the biopharmaceutical industry and will directly market the connector products once development is completed.

The firms say the INTACT connector technology will be the only multiple-use sterile connector to guarantee no contact between the liquid path and the external environment and ensures no ingress of air, bacteria, yeasts or mould.

  • Companies:
  • ATMI LifeSciences
See more

You may also like

Manufacturing

Opinion: Moving the goal posts

Read more
Suppliers of cleanroom technologies look set to benefit from the boom in biopharmaceuticals

Trending Articles

  1. Fume hoods: A guide to testing velocity A high airflow velocity is not a guarantee of containment. Qualification expert Jesus Casas walks you through the protocols required to make sure your velocity is spot on
  2. RABS, isolators and the track-and-trace trend Traditional aseptic production lines are a thing of the past. Isolators are being integrated with traceability systems to watch over safety of the product and the staff. Jorge Nuero of Telstar explains
  3. APIs: Bioreactor hoists with a multipurpose twist Peter Devenny of PalPharma describes the solution for a biotech facility in Switzerland designed to handle filled bioreactors across GMP areas to produce ten metric tons of antibody per year
  4. Micronclean Micronclean’s passion is to be the first to develop new technological solutions that change the shape of the markets we serve. Micronclean has been owned and managed by one family since the 1920’s and throughout our history, we have focused on quality, innovation, attention to detail and customer care.
  5. Solo Containment adds polyurethane half-suit to portfolio Polyurethane film has excellent mechanical properties and is free of phthalate, making it suitable for contact with pharmaceutical products

Upcoming event

Pharmig Annual Pharmaceutical Microbiology Conference

20–21 November 2024 | Conference | Nottingham, UK See all

You may also like

Manufacturing

Opinion: Moving the goal posts

Suppliers of cleanroom technologies look set to benefit from the boom in biopharmaceuticals
Manufacturing

ATMI opens US laboratory for bioprocess application support

Company brings successful lab approach from Europe to provide comprehensive solutions to North American customers at Bloomington site
Manufacturing

ATMI and Finesse Solutions sign distribution agreement

Will allow both companies to offer seamless support for single-use bioreactor systems
Manufacturing

ATMI and Disposable-Lab introduce first single-use platform for fill/finish operations

Offers a smaller footprint and is fully disposable
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Gas storage with no added pressures

Hazardous, toxic gases used in semiconductor fabrication are stored in and delivered from high-density media that adsorb gas molecules inside nano-sized pore structures, virtually eliminating accidental gas releases. ATMI’s BrightBlack precision nanoporous carbon has been specifically optimised for pore size and density to achieve the most favourable physical adsorption of these dangerous gas molecules.
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Leak detection in process vessels

In the manufacture of biologicals single-use disposable flexible vessels are commonly used as bioreactors, mixers and sterile fill stations. To guarantee the vessels are of the quality needed to ensure process integrity, they must be proven free from biological contamination and free of leaks that could be an ingress route for contaminants such as bacteria. The traditional pressure decay method has significant limitations, so ATMI has created a reliable and repeatable method involving pressurising the vessel with helium instead of air. By using this method, defects as small as 10µm can be easily detected.
Manufacturing

ATMI announces Helium Integrity Testing

Detects leaks from holes as small as 10 microns in single-use bioprocess vessels
Subscribe now